Form 4: Fairmount Funds Management Transfers Dianthus Therapeutics Shares Amid Fund Wind Down

Fairmount Funds Management LLC reports the transfer of Dianthus Therapeutics shares from Fairmount Healthcare Fund LP to Fairmount Healthcare Fund II LP as part of the former's wind down.

Summary

• On April 1, 2024, Fairmount Funds Management LLC reported changes in beneficial ownership of Dianthus Therapeutics, Inc. shares.
• The changes involve a transfer of 58,857 shares of common stock from Fairmount Healthcare Fund LP (Fund I) to Fairmount Healthcare Fund II LP (Fund II) due to the wind down of Fund I.
• Fairmount Funds Management LLC is the investment manager for both Fund I and Fund II.
• Tomas Kiselak, a managing member of Fairmount Funds Management GP LLC, serves on the board of directors of Dianthus Therapeutics, Inc.
• Fairmount Funds Management LLC, Fairmount Funds Management GP LLC, Peter Harwin, and Tomas Kiselak disclaim beneficial ownership of the securities held by Fund I, Fund II, and Fairmount SPV III, LLC, except to the extent of their pecuniary interest therein.
• After the transaction, Fairmount Healthcare Fund II LP holds 2,700,691 shares, and Fairmount SPV III, LLC holds 62,146 shares.

Sentiment

Score: 5

Explanation: The document is a routine regulatory filing related to internal fund restructuring, with no inherent positive or negative implications for the company's performance.

Industry Context

Form 4 filings are standard disclosures required by the SEC when there are changes in beneficial ownership of a company's securities by its directors, officers, or principal stockholders, providing transparency to the market.

Key Dates